Navigation Links
Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development
Date:2/11/2008

.

In addition, Pharmacopeia announced that enrollment in its ongoing Phase 2a PS433540 (DARA) clinical trial in subjects with Stage I and Stage II hypertension is progressing well. The trial remains on schedule with results expected in the second quarter of 2008.

PS433540 is a dual-acting angiotensin (AII) and endothelin (ET1) receptor antagonist (DARA) that is being developed as a potential treatment for hypertension and diabetic nephropathy. PS433540, the first and only DARA compound in development, possesses two clinically validated mechanisms of action in a single compound. There is considerable preclinical and initial clinical data suggesting that compared to either agent alone, simultaneously blocking the actions of both AII and ET1 may provide significantly improved treatment options for several cardiovascular diseases.

About Pharmacopeia

Pharmacopeia is a clinical development stage biopharmaceutical company dedicated to discovering and developing novel small molecule therapeutics to address significant medical needs. The company has a broad portfolio of clinical and preclinical candidates under development internally or by partners including seven clinical compounds in Phase 2 or Phase 1 development addressing multiple indications including hypertension, diabetic nephropathy, muscle wasting, inflammation and respiratory disease. The company is leveraging its fully integrated drug discovery platform to sustain the growth of its development pipeline. Pharmacopeia has established strategic agreements with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, Celgene, Cephalon, GlaxoSmithKline, Schering-Plough, and Wyeth Pharmaceuticals. For more information please visit the company's website at http://www.pharmacopeia.com.

Contact:

Amy P. Sharpless

Corporate Communications

Pharmacopeia, Inc.

609-452-3643

'/>"/>

SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmacopeia to Present at BIO CEO & Investor Conference 2008
2. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
3. Pharmacopeia Announces Third Quarter 2007 Financial Results
4. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
5. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
6. Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA)
7. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
10. Novel Small Molecule Therapy Shows Benefit for Anemic Patients Via Hydration of Red Blood Cells
11. CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... Nevro Corp. (NYSE: NVRO ), a ... solutions for the treatment of chronic pain, today announced ... its common stock consisting of 1,475,506 shares to be ... by certain of its stockholders. In addition, Nevro expects ... up to an additional 590,202 shares of common stock ...
(Date:6/1/2015)... MENLO PARK, Calif. , June ... (OTCQX: DMPI) ("DelMar" and the "Company"), a ... cancer therapies in new orphan drug indications, today ... clinical trial of  VAL-083  (dianhydrogalactitol) in patients with ... deadly form of human brain cancer. ...
(Date:6/1/2015)... 1, 2015 CEFALY Technology , the ... device specifically authorized for use prior to the onset ... new PET trial showing that the Cefaly device returns ... in migraine patients, namely the orbitofrontal cortex and rostral ... which is an imaging test of the brain, used a radioactive substance ...
Breaking Medicine Technology:Nevro Announces Proposed Public Offering of Common Stock 2Nevro Announces Proposed Public Offering of Common Stock 3DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 2DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 3DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 4DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 5DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 6DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 7DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 8New Study Shows CEFALY Returns Normal Metabolic Activity to Brain Areas in Migraine Patients 2
... 2011 /PRNewswire-Asia/ -- Winner Medical Group Inc. (Nasdaq: ... Company"), a leading manufacturer of medical dressings, medical ... PurCotton® products in China, today announced that the ... establish Shenzhen PurCotton E-Commerce Co., Ltd.("PurCotton E-Commerce"), aiming ...
... 29, 2011 Cardium Therapeutics (NYSE Amex: ... compliance plan designed to reestablish compliance with its exchange ... the acquisition of a revenue-generating nutraceutical business designed to ... matter, the Company announced the incorporation of MedPodium Health ...
Cached Medicine Technology:Winner Medical's PurCotton E-Commerce Sets Sail 2Winner Medical's PurCotton E-Commerce Sets Sail 3Winner Medical's PurCotton E-Commerce Sets Sail 4Cardium Provides Update on Exchange Listing and Related Business Matters 2Cardium Provides Update on Exchange Listing and Related Business Matters 3Cardium Provides Update on Exchange Listing and Related Business Matters 4Cardium Provides Update on Exchange Listing and Related Business Matters 5
(Date:6/1/2015)... June 02, 2015 The National ... Willey as a 2015-2016 inductee into its VIP ... with this prestigious distinction for leadership in safety, environment, ... networking organization exclusively for professional women, boasting more than ... "I’m pleased to present Lourinda with this important honor,” ...
(Date:6/1/2015)... 02, 2015 Dr. Robert ... Piedmont Physical Medicine & Rehabilitation, P.A., has published ... of stem cell therapy for knees, and highlights ... preferred alternative to arthroscopy or knee joint replacement. ... of Neuromusculoskeletal, Vascular and Regenerative Medicine, writes that ...
(Date:6/1/2015)... 01, 2015 Atagi Plastic Surgery and ... named an Ultherapy® Ultra Treatment Provider by ... Skin Aesthetics is one of only six practices in ... treatment provider. , Atagi Plastic Surgery and Skin ... area has led the practice to earn the distinction ...
(Date:6/1/2015)... 2015 The Muscular Dystrophy Association ... in participating in the sold out 2015 Bank ... secure guaranteed entry by signing up through the ... space is limited. , This national endurance program ... and abilities, and a supportive community of teammates, ...
(Date:6/1/2015)... (PRWEB) June 01, 2015 Note: Dr. ... development in breast cancer prevention. , A phase III ... that postmenopausal women with ductal carcinoma in situ (DCIS) ... and prevention. , The study (NSABP B-35/NRG Oncology) looked ... completed the standard five-year treatment with tamoxifen to those ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Inducts Lourinda Willey, Owner and Principal of Lourinda R. Willey LLC, Into its VIP Professional Woman of the Year Circle 2Health News:New Article by Dr. Robert G. Schwartz of Piedmont Physical Medicine & Rehabilitation Looks at Benefits of Stem Cell Therapy for Knees 2Health News:New Article by Dr. Robert G. Schwartz of Piedmont Physical Medicine & Rehabilitation Looks at Benefits of Stem Cell Therapy for Knees 3Health News:Atagi Plastic Surgery and Skin Aesthetics Named Ultherapy® Ultra Treatment Provider 2Health News:Sold Out 2015 Bank of America Chicago Marathon and Marine Corps Marathon Entries Still Available through MDA Team Momentum 2Health News:Today at ASCO: Anastrazole Offers Higher Breast Cancer-Free Survival Rates than Tamoxifen Following DCIS, Phase III Study Shows 2Health News:Today at ASCO: Anastrazole Offers Higher Breast Cancer-Free Survival Rates than Tamoxifen Following DCIS, Phase III Study Shows 3
... complication that can occur in children affected by acute ... attack, pulmonary embolism and other cardiovascular diseases//. ... Italy by the Laboratory of Genetic and Environmental Epidemiology ... collaboration with the Haematology Division of the University of ...
... Prexige is said to be linked to an increased risk ... warned to exercise caution in its use.// ,The ... Prexige (generic name, lumiracoxib) available from Tuesday. The drug is ... it was found in 2004 that these group of drugs ...
... have suggested that cross-immunity created in response to infection ... //,by related serotypes thus leading to the waxing and ... help understand the pattern of this deadly mosquito-borne illness ... 1980s, there's been a sequential replacement of the dominant ...
... Indiana University School of Medicine it was found that ... the life span of those suffering from compromised immune ... the journal of Biological Chemistry. These proteins can be ... boost the patient’s immune system. The lead researcher Roman ...
... been criticized severely because a staff nurse has refused to send ... Mary Smith, 87 had an agonizing pain in her lower abdomen. ... replied that she could not have an ambulance and had to ... her. Then when the GP arrived he just gave her some ...
... minds of many cancer survivors. After treatment, as life ... makers now //,consider a chronic condition, survivors need to ... choices to ensure quality-of-life. This national movement, commonly referred ... year. ,Steps for Living (SFL), a nonprofit ...
Cached Medicine News:Health News:Thrombosis, a Serious Risk in Children with Leukemia 2Health News:New Arthritis Drug Linked to Increased Risk of Heart Attacks 2Health News:Waxing And Waning Of Dengue Epidemics Attributed To Cross-Immunity 2Health News:Waxing And Waning Of Dengue Epidemics Attributed To Cross-Immunity 3Health News:New Music Project Promotes Quality-of-Life After Cancer 2
This EIA microplate opens new perspectives in the direct detection of Chlamydia. The choice of microplate immunoenzymatic technology and the use of a monoclonal antibody result in a combination of c...
... of rubella IgG antibody in women prior ... from possible rubella viral infection during pregnancy. ... greatly reduced the incidence of rubella epidemics, ... monitoring of immune status, especially for women ...
... Demonstration of rubella IgG antibody in women ... protection from possible rubella viral infection during ... has greatly reduced the incidence of rubella ... accurate monitoring of immune status, especially for ...
... Every Bard BrachyStar® Needle is designed ... an efficient and clinically effective brachytherapy procedure. ... featuring ultra-sharp tips and polished surfaces for ... of needle configurations and sizes assures an ...
Medicine Products: